NASDAQ · SCLXWHealthcareBiotechnology

Scilex Holding Company Warrant financials

$0.0880+40.35%
Close Sep 25, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
Revenue$30.3M$56.6M$46.7M$38.0M
Gross profit$19.7M$39.9M$31.1M$27.2M
Gross margin65.0%70.5%66.5%71.6%
Operating income-$346.0M-$83.4M-$105.4M-$50.6M
Net income-$402.5M-$72.8M-$167.0M-$23.4M
Net margin−1330.4%−128.7%−357.2%−61.4%
Diluted EPS$-36.48$-8.05$-44.80$-5.95
EBITDA-$267.7M-$88.7M-$101.3M-$46.7M
Operating cash flow$3.8M$19.3M-$20.7M-$21.3M
Free cash flow$3.7M$19.3M-$20.7M-$21.3M
Diluted shares11.0M10.1M3.7M3.8M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31
Cash & equivalents$5.0M$3.3M$3.9M$2.2M
Short-term investments$6.0M$0.00$0.00$0.00
Total debt$109.3M$35.7M$125.5M$0.00
Total assets$365.0M$93.0M$101.3M$86.5M
Total liabilities$576.7M$285.6M$274.2M$50.3M
Shareholders' equity-$211.8M-$192.6M-$172.9M$36.2M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology